glp-1 research papers Issue 42: RA Drug Development Glucagon-like peptide-1 receptor: mechanisms and

Abbreviations CKD: Chronic kidney disease DKA: Diabetic ketoacidosis FDA: US Food and Drug Administration GLP-1 RA: Glucagon-like peptide-1 receptor agonist HCO: Healthcare organisation IHD: Ischaemic heart disease PSM: Propensity score matching SGLT2i: Sodium-glucose cotransporter 2 inhibitor SSMD: Strictly standardised mean difference UTI: Urinary tract infection References Gregory GA, Robinson TIG, Linklater SE et al (2022) Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study

This slow titration reduces side effects like nausea while allowing your body to adapt to the medication's appetite-suppressing effects

These may indicate serious complications requiring urgent assessment

In the case of IDDM, the insulin is injected by syringe and is not secreted from the pancreas [15]

The change has prompted renewed attention from plaintiffs attorneys and drug-safety experts

While GLP-1 medications were originally developed for type 2 diabetes, they are now widely used to manage obesity and metabolic syndrome